blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4467984

EP4467984 - FIBROSIS BIOMARKER ASSAY [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  27.06.2025
Database last updated on 11.04.2026
FormerRequest for examination was made
Status updated on  17.01.2025
FormerThe application has been published
Status updated on  25.10.2024
Most recent event   Tooltip05.02.2026New entry: Renewal fee paid 
Applicant(s)For all designated states
Nordic Bioscience A/S
Herlev Hovedgade 207
2730 Herlev / DK
For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2024/48]
Inventor(s)01 / VEIDAL, Sanne
3650 Olstykke / DK
02 / KARSDAL, Morten
2100 København Ø / DK
03 / LEEMING, Diana Julie
3060 Espergaerde / DK
04 / BARASCUK MICHAELSEN, Natasha
2100 Copenhagen / DK
05 / SKJOT-ARKIL, Helene
2300 Copenhagen / DK
06 / SEGOVIA-SILVESTRE, Antonio
2200 Copenhagen / DK
07 / VASSILIADIS, Efstathios
2610 Rødovre / DK
 [2024/48]
Representative(s)Beck Greener LLP
Fulwood House
12 Fulwood Place
London WC1V 6HR / GB
[2024/48]
Application number, filing date24200645.029.03.2010
[2024/48]
Priority number, dateUS20090211467P30.03.2009         Original published format: US 211467 P
US20090289081P22.12.2009         Original published format: US 289081 P
[2024/48]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP4467984
Date:27.11.2024
Language:EN
[2024/48]
Type: A3 Search report 
No.:EP4467984
Date:04.12.2024
Language:EN
[2024/49]
Search report(s)(Supplementary) European search report - dispatched on:EP04.11.2024
ClassificationIPC:G01N33/68
[2024/48]
CPC:
G01N33/6893 (EP,KR,US); C12Q1/37 (EP,KR,US); G01N33/53 (KR);
G01N2333/4737 (US); G01N2333/78 (US); G01N2800/085 (US);
G01N2800/32 (EP,KR,US); G01N2800/50 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2024/48]
TitleGerman:FIBROSEBIOMARKERTEST[2024/48]
English:FIBROSIS BIOMARKER ASSAY[2024/48]
French:DOSAGE DE BIOMARQUEUR DE FIBROSE[2024/48]
Examination procedure15.01.2025Amendment by applicant (claims and/or description)
15.01.2025Examination requested  [2025/08]
15.01.2025Date on which the examining division has become responsible
27.06.2025Despatch of a communication from the examining division (Time limit: M04)
22.10.2025Reply to a communication from the examining division
Parent application(s)   TooltipEP10715752.1  / EP2414844
EP14169636.9  / EP2770327
EP16205956.2  / EP3173792
EP19174151.1  / EP3578664
Fees paidRenewal fee
16.09.2024Renewal fee patent year 03
16.09.2024Renewal fee patent year 04
16.09.2024Renewal fee patent year 05
16.09.2024Renewal fee patent year 06
16.09.2024Renewal fee patent year 07
16.09.2024Renewal fee patent year 08
16.09.2024Renewal fee patent year 09
16.09.2024Renewal fee patent year 10
16.09.2024Renewal fee patent year 11
16.09.2024Renewal fee patent year 12
16.09.2024Renewal fee patent year 13
16.09.2024Renewal fee patent year 14
16.09.2024Renewal fee patent year 15
04.02.2025Renewal fee patent year 16
04.02.2026Renewal fee patent year 17
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A] EP1150123  (BAYER AG et al.)
 [I]   ROBIN POOLE A ET AL: "The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 294, no. 1-2, 1 November 2004 (2004-11-01), pages 145 - 153, XP004679763, ISSN: 0022-1759, DOI: 10.1016/J.JIM.2004.09.005

DOI:   http://dx.doi.org/10.1016/j.jim.2004.09.005
 [A]   MOTRESCU E R ET AL: "Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions", ONCOGENE, NATURE PUBLISHING GROUP UK, LONDON, vol. 27, no. 49, 14 July 2008 (2008-07-14), pages 6347 - 6355, XP037744219, ISSN: 0950-9232, [retrieved on 20080714], DOI: 10.1038/ONC.2008.218

DOI:   http://dx.doi.org/10.1038/onc.2008.218
 [A]   HALFON P ET AL: "[Serum markers of non-invasive fibrosis in chronic hepatitis C virus infection]", REVUE DE MEDECINE INTERNE, ELSEVIER MASSON, FR, vol. 27, no. 10, 1 October 2006 (2006-10-01), pages 751 - 761, XP002596695, ISSN: 0248-8663, DOI: 10.1016/J.REVMED.2006.03.037

DOI:   http://dx.doi.org/10.1016/J.REVMED.2006.03.037
by applicantUS5387504
 US7225080
 US6060255
 US4628027
 WO2009059972
   HERTIG ET AL., J AM SOC NEPHROL., vol. 19, no. 8, August 2008 (2008-08-01), pages 1584 - 91
   MERIDEN ET AL., CLIN GASTRO & HEPATOL, vol. 8, 2010, pages 289 - 296
   GUANABENS NPARES AALVAREZ LMARTINEZ DE OSABA MJMONEGAL APERIS PBALLESTA AMRODES J.: "Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis", J BONE MINER RES, vol. 13, 1998, pages 731 - 738
   MOLLER SHANSEN MHILLINGSO JJENSEN JEHENRIKSEN JH: "Elevated carboxy terminal cross linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism", GUT, vol. 44, 1999, pages 417 - 423
   LEIN M, WIRTH M, MILLER K, EICKENBERG HU, WEISSBACH L, SCHMIDT K, HAUS U, STEPHAN C, MEISSNER S, LOENING SA, JUNG K.: "Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression", EUR UROL, 2007
   "NCBI", Database accession no. NM_012583.2
   TOMASEK JJGABBIANI GHINZ BCHAPONNIER CBROWN PA: "Myofibroblasts and mechano-regulation of connective tissue remodelling", NAT REV MOL CELL BIOL, vol. 3, 2002, pages 349 - 363
   WYNN TA.: "Cellular and molecular mechanisms of fibrosis", J PATHOL, vol. 214, 2008, pages 199 - 210, XP002553819, DOI: 10.1002/path.2277

DOI:   http://dx.doi.org/10.1002/path.2277
   FRIEDMAN SL: "Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications", NAT CLIN PRACT GASTROENTEROL HEPATOL, vol. 1, 2004, pages 98 - 105
   WYNN TA.: "Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases", J CLIN INVEST, vol. 117, 2007, pages 524 - 529, XP009137678
   MARCELLIN PASSELAH TBOYER N: "Fibrosis and disease progression in hepatitis C", HEPATOLOGY, vol. 36, 2002, pages S47 - S56
   GAGLIANO NAROSIO BGRIZZI FMASSON STAGLIABUE JDIOGUARDI NVERGANI CANNONI G: "Reduced collagenolytic activity of matrix metalloproteinases and development of liver fibrosis in the aging rat", MECH AGEING DEV, vol. 123, 2002, pages 413 - 425
   LAURENT GJ: "Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass", AM J PHYSIOL, vol. 252, 1987, pages C1 - C9
   MAYS PKMCANULTY RJCAMPA JSLAURENT GJ: "Age-related changes in collagen synthesis and degradation in rat tissues. Importance of degradation of newly synthesized collagen in regulating collagen production", BIOCHEM J, vol. 276, no. 2, 1991, pages 307 - 313
   GARRONE RLETHIAS CLE GUELLEC D: "Distribution of minor collagens during skin development.", MICROSC RES TECH, vol. 38, 1997, pages 407 - 412
   GELSE KPOSCHL EAIGNER T: "Collagens--structure, function, and biosynthesis", ADV DRUG DELIV REV, vol. 55, 2003, pages 1531 - 1546, XP055665967, DOI: 10.1016/j.addr.2003.08.002

DOI:   http://dx.doi.org/10.1016/j.addr.2003.08.002
   TOYAMA-SORIMACHI NSORIMACHI HTOBITA YKITAMURA FYAGITA HSUZUKI KMIYASAKA M: "A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation", J BIOL CHEM, vol. 270, 1995, pages 7437 - 7444
   MARTINEZ-HERNANDEZ A, AMENTA PS.: "The hepatic extracellular matrix. II. Ontogenesis, regeneration and cirrhosis.", VIRCHOWS ARCH A PATHOL ANAT HISTOPATHOL, vol. 423, 1993, pages 77 - 84
   GILLIAM AC, SCLERODERMA. CURR DIR AUTOIMMUN, vol. 10, 2008, pages 258 - 279
   GRESSNER AMWEISKIRCHEN R: "Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets", J CELL MOL MED, vol. 10, 2006, pages 76 - 99
   HEINEGARD DOLDBERG A: "Structure and biology of cartilage and bone matrix noncollagenous macromolecules", FASEB J, vol. 3, 1989, pages 2042 - 2051
   SVENSSON LOLDBERG AHEINEGARD D.: "Collagen binding proteins", OSTEOARTHRITIS AND CARTILAGE, vol. 9, 2001, pages S23 - S28
   KIANI CCHEN LWU YJYEE AJYANG BB: "Structure and function of aggrecan", CELL RES, vol. 12, 2002, pages 19 - 32
   KRUSIUS TGEHLSEN KRRUOSLAHTI E: "A fibroblast chondroitin sulfate proteoglycan core protein contains lectin-like and growth factor-like sequences", J BIOL CHEM, vol. 262, 1987, pages 13120 - 13125
   YANG BLZHANG YCAO LYANG BB: "Cell adhesion and proliferation mediated through the G1 domain of versican", J CELL BIOCHEM, vol. 72, 1999, pages 210 - 220
   RAUCH UKARTHIKEYAN LMAUREL PMARGOLIS RUMARGOLIS RK: "Cloning and primary structure of neurocan, a developmentally regulated, aggregating chondroitin sulfate proteoglycan of brain", J BIOL CHEM, vol. 267, 1992, pages 19536 - 19547
   YAMADA HWATANABE KSHIMONAKA MYAMAGUCHI Y: "Molecular cloning of brevican, a novel brain proteoglycan of the aggrecan/versican family", J BIOL CHEM, vol. 269, 1994, pages 10119 - 10126, XP002266635
   BLOCHBERGER TCCORNUET PKHASSELL JR: "Isolation and partial characterization of lumican and decorin from adult chicken corneas. A keratan sulfate-containing isoform of decorin is developmentally regulated", J BIOL CHEM, vol. 267, 1992, pages 20613 - 20619
   FISHER LWTERMINE JDYOUNG MF: "Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species", J BIOL CHEM, vol. 264, 1989, pages 4571 - 4576, XP055169896
   BARTLETT AHHAYASHIDA KPARK PW: "Molecular and cellular mechanisms of syndecans in tissue injury and inflammation", MOL CELLS, vol. 24, 2007, pages 153 - 166
   LOPEZ-CASILLAS FWRANA JLMASSAGUE J.: "Betaglycan presents ligand to the TGF beta signaling receptor", CELL, vol. 73, 1993, pages 1435 - 1444
   OLSEN BR: "Life without perlecan has its problems", J CELL BIOL, vol. 147, 1999, pages 909 - 912
   GABAY CKUSHNER I: "Acute-phase proteins and other systemic responses to inflammation", N ENGL J MED, vol. 340, 1999, pages 448 - 454, XP008003139, DOI: 10.1056/NEJM199902113400607

DOI:   http://dx.doi.org/10.1056/NEJM199902113400607
   BENYON RCARTHUR MJ: "Extracellular matrix degradation and the role of hepatic stellate cells", SEMIN LIVER DIS, vol. 21, 2001, pages 373 - 384
   GUO JFRIEDMAN SL: "Hepatic fibrogenesis", SEMIN LIVER DIS, vol. 27, 2007, pages 413 - 426
   IREDALE JPBENYON RCARTHUR MJFERRIS WFALCOLADO RWINWOOD PJCLARK NMURPHY G: "Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis", HEPATOLOGY, vol. 24, 1996, pages 176 - 184
   LEE KNJACKSON KWCHRISTIANSEN VJLEE CSCHUN JGMCKEE PA: "Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein", BLOOD, vol. 107, 2006, pages 1397 - 1404, XP002394322, DOI: 10.1182/blood-2005-08-3452

DOI:   http://dx.doi.org/10.1182/blood-2005-08-3452
   ACHARYA PSZUKAS ACHANDAN VKATZENSTEIN ALPURE E: "Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis", HUM PATHOL, vol. 37, 2006, pages 352 - 360, XP005301569, DOI: 10.1016/j.humpath.2005.11.020

DOI:   http://dx.doi.org/10.1016/j.humpath.2005.11.020
   LEVY MTMCCAUGHAN GWMARINOS GGORRELL MD: "Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection", LIVER, vol. 22, 2002, pages 93 - 101, XP002352239, DOI: 10.1034/j.1600-0676.2002.01503.x

DOI:   http://dx.doi.org/10.1034/j.1600-0676.2002.01503.x
   MEYER O: "Prognostic markers for systemic sclerosis", JOINT BONE SPINE, vol. 73, 2006, pages 490 - 494, XP028072867, DOI: 10.1016/j.jbspin.2006.01.022

DOI:   http://dx.doi.org/10.1016/j.jbspin.2006.01.022
   HUMMERS LK: "Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers", CURR RHEUMATOL REP, vol. 8, 2006, pages 131 - 137
   MCHUGH NJDISTLER OGIACOMELLI RRIEMEKASTEN G: "Non organ based laboratory markers in systemic sclerosis", CLIN EXP RHEUMATOL, vol. 21, 2003, pages S32 - S38
   MULLER-QUERNHEIM J.: "Serum markers for the staging of disease activity of sarcoidosis and other interstitial lung diseases of unknown etiology", SARCOIDOSIS VASC DIFFUSE LUNG DIS, vol. 15, 1998, pages 22 - 37
   GRESSNER OAWEISKIRCHEN RGRESSNER AM: "Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests.", CLIN CHIM ACTA, vol. 381, 2007, pages 107 - 113, XP022072413, DOI: 10.1016/j.cca.2007.02.038

DOI:   http://dx.doi.org/10.1016/j.cca.2007.02.038
   GRESSNER OAWEISKIRCHEN RGRESSNER AM: "Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality", J CELL MOL MED, vol. 11, 2007, pages 1031 - 1051
   MARIAT C: "Diagnosis and follow-up of chronic kidney graft dysfunction: from DFG to new biomarkers", NEPHROL THER, vol. 4, no. 3, 2008, pages S204 - S207
   YONEDA MMAWATARI HFUJITA KIIDA HYONEMITSU KKATO STAKAHASHI HKIRIKOSHI HINAMORI MNOZAKI Y: "High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH", J GASTROENTEROL, vol. 42, 2007, pages 573 - 582, XP019543697, DOI: 10.1007/s00535-007-2060-x

DOI:   http://dx.doi.org/10.1007/s00535-007-2060-x
   WONG VSHUGHES VTRULL AWIGHT DGPETRIK JALEXANDER GJ: "Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection", J VIRAL HEPAT, vol. 5, 1998, pages 187 - 192, XP002430230, DOI: 10.1046/j.1365-2893.1998.00100.x

DOI:   http://dx.doi.org/10.1046/j.1365-2893.1998.00100.x
   PARISE EROLIVEIRA ACFIGUEIREDO-MENDES CLANZONI VMARTINS JNADER HFERRAZ ML: "Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection", LIVER INT, vol. 26, 2006, pages 1095 - 1099
   MCHUTCHISON JGBLATT LMDE MEDINA MCRAIG JRCONRAD ASCHIFF ERTONG MJ: "Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group", J GASTROENTEROL HEPATOL, vol. 15, 2000, pages 945 - 951
   CAMACHO VRSILVEIRA TROLIVEIRA JRBARROS SGCERSKI CT: "Relationship between serum concetrations of type III procollagen, hyluronic acid and histopathological findings in the liver of HCV-positive blood donors", ARQ GASTROENTEROL, vol. 44, 2007, pages 118 - 122
   LORENZO-ZUNIGA VBARTOLI RMASNOU HMONTOLIU SMORILLAS RMPLANAS R: "Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C", DIG DIS SCI, vol. 52, 2007, pages 3245 - 3250, XP019550430, DOI: 10.1007/s10620-006-9437-1

DOI:   http://dx.doi.org/10.1007/s10620-006-9437-1
   MANOLAKOPOULOS SBETHANIS SLIAPI CSTRIPELI FSKLAVOS PMARGELI ACHRISTIDOU AKATSANIKA AVOGIATZAKIS ETZOURMAKLIOTIS D: "An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study", BMC GASTROENTEROL, vol. 7, 2007, pages 17, XP021028846, DOI: 10.1186/1471-230X-7-17

DOI:   http://dx.doi.org/10.1186/1471-230X-7-17
   LEROY VHILLERET MNSTURM NTROCME CRENVERSEZ JCFAURE PMOREL FZARSKI JP: "Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C", J HEPATOL, vol. 46, 2007, pages 775 - 782, XP022024083, DOI: 10.1016/j.jhep.2006.12.013

DOI:   http://dx.doi.org/10.1016/j.jhep.2006.12.013
   TROCME CLEROY VSTURM NHILLERET MNBOTTARI SMOREL FZARSKI JP: "Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin", J VIRAL HEPAT, vol. 13, 2006, pages 643 - 651
   ZHENG MCAI WMWENG HLLIU RH: "ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis", WORLD J GASTROENTEROL, vol. 8, 2002, pages 1073 - 1076
   LEBENSZTEJN DMSOBANIEC-LOTOWSKA MEBAUER MKACZMARSKI MVOELKER MSCHUPPAN D: "Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B", EUR J GASTROENTEROL HEPATOL, vol. 17, 2005, pages 843 - 848
   LEBENSZTEJN DMSOBANIEC-LOTOWSKA MEKACZMARSKI MVOELKER MSCHUPPAN D: "Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha", WORLD J GASTROENTEROL, vol. 12, 2006, pages 3338 - 3343
   TSOCHATZIS EPAPATHEODORIDIS GVHADZIYANNIS EGEORGIOU AKAFIRI GTINIAKOS DGMANESIS EKARCHIMANDRITIS AJ: "Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity", SCAND J GASTROENTEROL, vol. 43, 2008, pages 1128 - 1136
   PATEL KGORDON SCJACOBSON IHEZODE COH ESMITH KMPAWLOTSKY JMMCHUTCHISON JG: "Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients", J HEPATOL, vol. 41, 2004, pages 935 - 942, XP004776471, DOI: 10.1016/j.jhep.2004.08.008

DOI:   http://dx.doi.org/10.1016/j.jhep.2004.08.008
   LIEBER CSWEISS DGPARONETTO F: "Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease", ALCOHOL CLIN EXP RES, vol. 32, 2008, pages 1031 - 1039, XP071476598, DOI: 10.1111/j.1530-0277.2008.00664.x

DOI:   http://dx.doi.org/10.1111/j.1530-0277.2008.00664.x
   FORNS XAMPURDANES SLLOVET JMAPONTE JQUINTO LMARTINEZ-BAUER EBRUGUERA MSANCHEZ-TAPIAS JMRODES J.: "Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model", HEPATOLOGY, vol. 36, 2002, pages 986 - 992
   BOURLIERE MPENARANDA GRENOU CBOTTA-FRIDLUND DTRAN APORTAL ILECOMTE LCASTELLANI PROSENTHAL-ALLIERI MAGEROLAMI R: "Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies", J VIRAL HEPAT, vol. 13, 2006, pages 659 - 670
   CACOUB PCARRAT FBEDOSSA PLAMBERT JPENARANDA GPERRONNE CPOL SHALFON P: "Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02", J HEPATOL, vol. 48, 2008, pages 765 - 773, XP022627179, DOI: 10.1016/j.jhep.2008.01.025

DOI:   http://dx.doi.org/10.1016/j.jhep.2008.01.025
   NUNES DFLEMING COFFNER GO'BRIEN MTUMILTY SFIX OHEEREN TKOZIEL MGRAHAM CCRAVEN DE: "HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease", J ACQUIR IMMUNE DEFIC SYNDR, vol. 40, 2005, pages 538 - 544
   GRIGORESCU MRUSU MNECULOIU DRADU CSERBAN ACATANAS MGRIGORESCU MD: "The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients", THE ROMANIAN EXPERIENCE. J GASTROINTESTIN LIVER DIS, vol. 16, 2007, pages 31 - 37
   HALFON PBACQ YDE MAPENARANDA GBOURLIERE MOUZAN DTRAN ABOTTA DRENOU CBRECHOT MC: "Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C", J HEPATOL, vol. 46, 2007, pages 395 - 402
   HALFON PBOURLIERE MDEYDIER RBOTTA-FRIDLUND DRENOU CTRAN APORTAL IALLEMAND IBERTRAND JJROSENTHAL-ALLIERI A: "Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study", AM J GASTROENTEROL, vol. 101, 2006, pages 547 - 555
   LEROY VHALFON PBACQ YBOURSIER JROUSSELET MCBOURLIERE MDE MASTURM NHUNAULT GPENARANDA G: "Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data", CLIN BIOCHEM, vol. 41, 2008, pages 1368 - 1376, XP025613176, DOI: 10.1016/j.clinbiochem.2008.06.020

DOI:   http://dx.doi.org/10.1016/j.clinbiochem.2008.06.020
   RATZIU VMASSARD JCHARLOTTE FMESSOUS DIMBERT-BISMUT FBONYHAY LTAHIRI MMUNTEANU MTHABUT DCADRANEL JF: "Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease", BMC GASTROENTEROL, vol. 6, 2006, pages 6, XP021015515, DOI: 10.1186/1471-230X-6-6

DOI:   http://dx.doi.org/10.1186/1471-230X-6-6
   POYNARD TIMBERT-BISMUT FRATZIU VCHEVRET SJARDEL CMOUSSALLI JMESSOUS DDEGOS F: "Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.", J VIRAL HEPAT, vol. 9, 2002, pages 128 - 133, XP055020656, DOI: 10.1046/j.1365-2893.2002.00341.x

DOI:   http://dx.doi.org/10.1046/j.1365-2893.2002.00341.x
   POYNARD T, MUNTEANU M, IMBERT-BISMUT F, CHARLOTTE F, THABUT D, LE CS, MESSOUS D, THIBAULT V, BENHAMOU Y, MOUSSALLI J, RATZIU V.: "Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C", CLIN CHEM, vol. 50, 2004, pages 1344 - 1355
   POYNARD TMORRA RHALFON PCASTERA LRATZIU VIMBERT-BISMUT FNAVEAU STHABUT DLEBREC DZOULIM F: "Meta-analyses of FibroTest diagnostic value in chronic liver disease", BMC GASTROENTEROL, vol. 7, 2007, pages 40, XP021034074
   NGO YMUNTEANU MMESSOUS DCHARLOTTE FIMBERT-BISMUT FTHABUT DLEBRAY PTHIBAULT VBENHAMOU YMOUSSALLI J: "A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C", CLIN CHEM, vol. 52, 2006, pages 1887 - 1896
   NAVEAU SRAYNARD BRATZIU VABELLA AIMBERT-BISMUT FMESSOUS DBEUZEN FCAPRON FTHABUT DMUNTEANU M: "Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease", CLIN GASTROENTEROL HEPATOL, vol. 3, 2005, pages 167 - 174, XP005120681, DOI: 10.1016/S1542-3565(04)00625-1

DOI:   http://dx.doi.org/10.1016/S1542-3565(04)00625-1
   MYERS RPTAINTURIER MHRATZIU VPITON ATHIBAULT VIMBERT-BISMUT FMESSOUS DCHARLOTTE FDI M, VBENHAMOU Y: "Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B", J HEPATOL, vol. 39, 2003, pages 222 - 230, XP002400897, DOI: 10.1016/S0168-8278(03)00171-5

DOI:   http://dx.doi.org/10.1016/S0168-8278(03)00171-5
   JACQUEMINET S, LEBRAY P, MORRA R, MUNTEANU M, DEVERS L, MESSOUS D, BERNARD M, HARTEMANN-HEURTIER A, IMBERT-BISMUT F, RATZIU V, GRI: "Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes", CLIN GASTROENTEROL HEPATOL, vol. 6, 2008, pages 828 - 831, XP023436331, DOI: 10.1016/j.cgh.2008.03.005

DOI:   http://dx.doi.org/10.1016/j.cgh.2008.03.005
   NUNES DFLEMING COFFNER GO'BRIEN MTUMILTY SFIX OHEEREN TKOZIEL MGRAHAM CCRAVEN DE: "Jr. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease", J ACQUIR IMMUNE DEFIC SYNDR, vol. 40, 2005, pages 538 - 544
   POYNARD TZOULIM FRATZIU VDEGOS FIMBERT-BISMUT FDENY PLANDAIS PEL HASLAMA ABLIN P: "Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection", AM J GASTROENTEROL, vol. 100, 2005, pages 1970 - 1980
   CARVALHO-FILHO RJSCHIAVON LLNARCISO-SCHIAVON JLSAMPAIO JPLANZONI VPFERRAZ MLSILVA AE: "Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection", LIVER INT, vol. 28, 2008, pages 486 - 493
   AL-MOHRI HCOOPER CMURPHY TKLEIN MB: "Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients", HIV MED, vol. 6, 2005, pages 375 - 378
   CALES P, LAINE F, BOURSIER J, DEUGNIER Y, MOAL V, OBERTI F, HUNAULT G, ROUSSELET MC, HUBERT I, LAAFI J, DUCLUZEAUX PH, LUNEL F.: "Comparison of blood tests for liver fibrosis specific or not to NAFLD", J HEPATOL, 2008
   PAGGI SCOLLI AFRAQUELLI MVIGANO MDEL PPFACCIOTTO CCOLOMBO MRONCHI GCONTE D: "A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal-external validation", J HEPATOL, vol. 49, 2008, pages 564 - 571, XP025432163, DOI: 10.1016/j.jhep.2008.07.007

DOI:   http://dx.doi.org/10.1016/j.jhep.2008.07.007
   TRANG TPETERSEN JRSNYDER N: "Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: comparison of the APRI and FIB-4 index", CLIN CHIM ACTA, vol. 397, 2008, pages 51 - 54, XP025408968, DOI: 10.1016/j.cca.2008.07.009

DOI:   http://dx.doi.org/10.1016/j.cca.2008.07.009
   SNYDER NGAJULA LXIAO SYGRADY JLUXON BLAU DTSOLOWAY RPETERSEN J.: "APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C", J CLIN GASTROENTEROL, vol. 40, 2006, pages 535 - 542
   SNYDER NNGUYEN AGAJULA LSOLOWAY RXIAO SYLAU DTPETERSEN J.: "The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C", CLIN CHIM ACTA, vol. 381, 2007, pages 119 - 123, XP022072415, DOI: 10.1016/j.cca.2007.02.046

DOI:   http://dx.doi.org/10.1016/j.cca.2007.02.046
   HONGBO LXIAOHUI LHONG KWEI WYONG Z: "Assessing routine and serum markers of liver fibrosis in CHB patients using parallel and serial interpretation", CLIN BIOCHEM, vol. 40, 2007, pages 562 - 566, XP022036491, DOI: 10.1016/j.clinbiochem.2007.01.022

DOI:   http://dx.doi.org/10.1016/j.clinbiochem.2007.01.022
   ADAMS LABULSARA MROSSI EDEBOER BSPEERS DGEORGE JKENCH JFARRELL GMCCAUGHAN GWJEFFREY GP: "Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection", CLIN CHEM, vol. 51, 2005, pages 1867 - 1873
   KODA MMATUNAGA YKAWAKAMI MKISHIMOTO YSUOU TMURAWAKI Y: "FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C", HEPATOLOGY, vol. 45, 2007, pages 297 - 306, XP071560324, DOI: 10.1002/hep.21520

DOI:   http://dx.doi.org/10.1002/hep.21520
   METWALLY MAZEIN COZEIN NN: "Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C", DIG DIS SCI, vol. 52, 2007, pages 582 - 588, XP019464792, DOI: 10.1007/s10620-006-9366-z

DOI:   http://dx.doi.org/10.1007/s10620-006-9366-z
   MOHAMADNEJAD MMONTAZERI GFAZLOLLAHI AZAMANI FNASIRI JNOBAKHT HFOROUZANFAR MHABEDIAN STAVANGAR SMMOHAMADKHANI A: "Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease", AM J GASTROENTEROL, vol. 101, 2006, pages 2537 - 2545
   ZAMAN AROSEN HRINGRAM KCORLESS CLOH ESMITH K: "Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients", AM J MED, vol. 120, 2007, pages 280 - 14, XP005929973, DOI: 10.1016/j.amjmed.2006.06.044

DOI:   http://dx.doi.org/10.1016/j.amjmed.2006.06.044
   PATEL KNELSON DRROCKEY DCAFDHAL NHSMITH KMOH EHETTINGER KVALLEE MDEV ASMITH-RIGGS M: "Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C", CLIN GASTROENTEROL HEPATOL, vol. 6, 2008, pages 242 - 247, XP022472072, DOI: 10.1016/j.cgh.2007.11.009

DOI:   http://dx.doi.org/10.1016/j.cgh.2007.11.009
   SEBASTIANI GVARIO AGUIDO MNOVENTA FPLEBANI MPISTIS RFERRARI AALBERTI A: "Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C", J HEPATOL, vol. 44, 2006, pages 686 - 693, XP025054421, DOI: 10.1016/j.jhep.2006.01.007

DOI:   http://dx.doi.org/10.1016/j.jhep.2006.01.007
   IMBERT-BISMUT F, RATZIU V, PIERONI L, CHARLOTTE F, BENHAMOU Y, POYNARD T.: "Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study", LANCET, vol. 357, 2001, pages 1069 - 1075, XP005061312, DOI: 10.1016/S0140-6736(00)04258-6

DOI:   http://dx.doi.org/10.1016/S0140-6736(00)04258-6
   CASTERA LVERGNIOL JFOUCHER JLE BBCHANTELOUP EHAASER MDARRIET MCOUZIGOU P, DE L, V: "Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C", GASTROENTEROLOGY, vol. 128, 2005, pages 343 - 350, XP005313375, DOI: 10.1053/j.gastro.2004.11.018

DOI:   http://dx.doi.org/10.1053/j.gastro.2004.11.018
   ROSEN HNPARKER RAGREENSPAN SLILOPUTAIFE IDBOOKMAN LCHAPIN DPERLMUTTER IKESSEL BQVIST PROSENBLATT M: "Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT", CALCIF TISSUE INT, vol. 74, 2004, pages 415 - 423
   ATTALLAH AMTOSON EASHIHA GEOMRAN MMBDEL-AZIZ MMEL-DOSOKY I: "Evaluation of serum procollagen aminoterminal propeptide III, laminin, and hydroxyproline as predictors of severe fibrosis in patients with chronic hepatitis C", J IMMUNOASSAY IMMUNOCHEM, vol. 28, 2007, pages 199 - 211
   ULRICH DNOAH EMVON HD, PALLUA N: "TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma", PLAST RECONSTR SURG, vol. 111, 2003, pages 1423 - 1431, XP009079248, DOI: 10.1097/01.PRS.0000049450.95669.07

DOI:   http://dx.doi.org/10.1097/01.PRS.0000049450.95669.07
   FARKKILA M, RAUTIAINEN H, KARKKAINEN P, KARVONEN AL, NURMI H, NIEMELA O.: "Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy", LIVER INT, vol. 28, 2008, pages 787 - 797
   GUECHOT J, POUPON RE, GIRAL P, BALKAU B, GIBOUDEAU J, POUPON R.: "Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C", J HEPATOL, vol. 20, 1994, pages 388 - 393, XP029122232, DOI: 10.1016/S0168-8278(94)80013-8

DOI:   http://dx.doi.org/10.1016/S0168-8278(94)80013-8
   KLAPPACHER G, FRANZEN P, HAAB D, MEHRABI M, BINDER M, PLESCH K, PACHER R, GRIMM M, PRIBILL I, EICHLER HG: "Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis", AM J CARDIOL, vol. 75, 1995, pages 913 - 918, XP005495667, DOI: 10.1016/S0002-9149(99)80686-9

DOI:   http://dx.doi.org/10.1016/S0002-9149(99)80686-9
   SUZUKI,K., ENGHILD,J.J., MORODOMI,T., SALVESEN,G., AND NAGASE,H.: "Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin", BIOCHEMISTRY, vol. 29, 1990, pages 10261 - 10270
   LIJNEN,H.R.: "Plasmin and matrix metalloproteinases in vascular remodeling", THROMB. HAEMOST., vol. 86, 2001, pages 324 - 333
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.